Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MicuRx Raises $55 Million for China-US Development of Novel Antibiotic

publication date: Sep 26, 2016
MicuRx Pharma, a San Francisco-Shanghai antibiotics company, closed a $55 million Series C financing from China investors. MicuRx said the money would be enough to complete clinical development of MRX-I in China and US, including a China filing for approval of the drug. MRX-1 is an oral, next-gen oxazolidinone antibacterial designed to combat drug-resistant infections. The C round was led by GP Healthcare Capital and joined by new investors GP TMT Capital, 3E Bioventures Capital and Delian Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital